EPO Patents = 6

Trademarks = 3

Forward Citations = 39

Loading Chart...

1 inventor (with patents filed for the assignee):

Robert Stuart Coffin (11 out of 26 patents)

11 patents: Sort by Forward Citations

1. 12458696 - Modified oncolytic virus (2025-11-04),

2. 12397053 - Engineered virus (2025-08-26),

3. 12059444 - Altered virus (2024-08-13),

4. 12049647 - Engineered virus (2024-07-30),

5. 12024724 - Oncolytic virus strain (2024-07-02),

6. 11473063 - Oncolytic virus strain (2022-10-18),

7. 11427810 - Modified oncolytic virus (2022-08-30),

8. 10947513 - Engineered virus (2021-03-16),

9. 10626377 - Use of an oncolytic virus for the treatment of cancer (2020-04-21),

10. 10612005 - Modified oncolytic virus (2020-04-07),

11. 10570377 - Oncolytic virus strain (2020-02-25),

Replimune Limited is a clinical-stage biotechnology company focused on the development of oncolytic immunotherapies for the treatment of cancer. Their innovative platform enables the specific targeting and killing of tumor cells while also activating the immune system to mount a robust anti-tumor response. With a strong pipeline of potential therapies, Replimune is dedicated to improving outcomes for cancer patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

11 Patents

#19 in Oxford

#1,553 in United Kingdom

#50,205 in the World

Oxford, United Kingdom

Replimune Limited

Forward Citations = 39

1 inventor:

Robert Stuart Coffin (11 out of 26 patents)

Please report any incorrect information to support@idiyas.com

6 patents (EPO):

Please report any incorrect information to support@idiyas.com